City

Bethesda (1)

Singapore (1)

Overall Status

Active, not recruiting (1)

Recruiting (1)

Sign in for free

Phase

phase 1 (1)

phase 2 (1)

Sponsor

National Cancer Institute (NCI) (1)

Novartis Pharmaceuticals (1)

Collaborator

Intervention

azd6244 (1)

erlotinib (1)

kfa115 (1)

lapatinib (1)

mk-2206 (1)

molecular profiling (1)

sunitinib (1)

tislelizumab (1)

Study Documents

Intervention Type

drug (2)

procedure (1)

Funder Type

Industry (1)

NIH (1)

Study Type

Interventional (2)

carcinoma, thymic

Showing 1 - 2 of 2

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

NSCLC, Cutaneous Melanoma, Carcinoma, Renal Cell Trial (KFA115, tislelizumab)

Recruiting

Carcinoma, Non-Small-Cell Lung
+10 more

Singapore, Singapore

Novartis Investigative Site

Nov 16, 2022

NSCLC, Carcinoma, Small Cell Lung, Carcinoma, Thymic Trial run by the National Cancer Institute (NCI) (AZD6244, MK-2206,

Active, not recruiting

Carcinoma, Non-Small-Cell Lung
+2 more

AZD6244
+5 more

Bethesda, Maryland

National Institutes of Health Clinical Center, 9000 Rockville Pi

Aug 24, 2022